⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OGN News
Organon & Co.
SAS Innovate 2026 to feature new health care and life sciences AI capabilities and real-world use cases
prnewswire.com
JNJ
AZN
GILD
REGN
SNY
IQV
OGN
PFE
ABBV
ELV
CI
Organon Debuts New Analysis of VTAMA ® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
businesswire.com
OGN
Alger Russell Innovation Index Updates for First Quarter 2026
prnewswire.com
CORT
DT
GTLB
PAYC
PCOR
PEGA
PSTG
TTD
ALGN
DOX
ENPH
FFIV
GNTX
MRK
MTCH
OGN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out
accessnewswire.com
OGN
Humegon (Organon) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
OGN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
OGN
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
accessnewswire.com
OGN
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Shareholders to Inquire about Securities Investigation
accessnewswire.com
OGN
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS
globenewswire.com
OGN
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
OGN